DR. HANG HUBERT YIN, PHD

Professor and State Specially Recruited Expert, School of Pharmaceutical Sciences, Tsinghua University, Beijing China

Small Molecule Immunomodulators that Target Toll-Like Receptors

JOSHUA E. ALLEN, PHD

Senior Vice President - Research & Development, Oncoceutics, Inc.

Phenotypic discovery of the first DRD2-targeting agent for clinical oncology

DR. PAUL J. DAVIS, M.D.

Department of Medicine, Albany Medical College, Albany, NY USA; Pharmaceutical Research Institute, Albany College of Pharmacy and Health Sciences, Albany, NY USA; Taipei Cancer Center, Taipei Medical University, Taipei, Taiwan

The Thyroid Hormone Receptor on the Cancer Cell Plasma Membrane Integrin avB3 Regulates Cell Proliferation, Anti-Apoptosis, Immune Checkpoint Defense and Angiogenesis

DR. DITYA BARDIA, MD, MPH

Assistant Professor, Medicine, Harvard Medical School Attending Physician, Medical Oncology, Massachusetts General Hospital

Antibody Drug Conjugates for Treatment of Breast Cancer: The Next Generation of Targeted Chemotherapeutics.

DR. JEFFREY LEYTON, PH.D.

Assistant Professor, Department of Nuclear Medicine and Radiobiology, Faculty of Medicine and Health Sciences, Université de Sherbrooke – CHUS

ADCs with integrated endosome escape and nuclear-directional intracellular trafficking-control capabilities – An approach for next-generation cancer therapeutics

DR. MARIA LUZ JARAMILLO, Ph.D.

Senior Research Officer and ADC Project Lead Primary Assays Team Life Sciences - NRC Human Health Therapeutics Portfolio National Research Council Canada

Antibody and ADC development at National Research Council

DR. DAVID M. PERRIN

Chemistry Department, University of British Columbia, Vancouver, BC Canada

From new F18-PET imaging agents to targeted toxins for therapy

DR. WAYNE GUIDA

Professor & Chair of the Chemistry Dept.
University of South Florida
Tampa, Florida, USA

Drug Discovery Research Symposium